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Abstract 
Diesel exhaust particles (DEPs) are common environmental air pollutants known to impair 
expression and activity of drug detoxifying proteins, including hepatic ATP-binding cassette 
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(ABC) drug transporters. The present study was designed to determine whether organic DEP 
extract (DEPe) may also target ABC drug transporters in bronchial cells. DEPe (10 µg/mL) 
was demonstrated to induce mRNA and protein expression of the multidrug resistance-
associated protein (MRP) 3 in cultured bronchial epithelial BEAS-2B cells, whereas mRNA 
levels of other MRPs, multidrug resistance gene 1 or breast cancer resistance protein were 
unchanged, reduced or not detected. DEPe also increased MRP3 mRNA expression in normal 
human bronchial epithelial cells. Inhibition of the aryl hydrocarbon receptor (AhR) pathway 
by AhR antagonists or AhR silencing, as well as the silencing of nuclear-factor-E2-related 
factor 2 (Nrf2) repressed DEPe-mediated MRP3 induction. This underlines the implication of 
the AhR and Nrf2 signaling cascades in DEPe-mediated MRP3 regulation. DEPe was 
additionally demonstrated to directly inhibit MRP activity in BEAS-2B cells, in a 
concentration-dependent manner. Taken together, these data indicate that DEPs may impair 
expression and activity of MRPs, notably MRP3, in human bronchial cells, which may have 
consequences in terms of lung barrier and toxicity for humans exposed to diesel pollution.   
Key-words: Drug transporter; MRP3; diesel exhaust; bronchial cells; aryl hydrocarbon 
receptor; Nrf2. 
 
 
 
 
 
1. Introduction 
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Human ATP-binding cassette (ABC) drug transporters are plasma membrane proteins 
mediating cellular efflux of xenobiotics (Schinkel and Jonker, 2003). They have been 
historically characterized as efflux pumps reducing anticancer drug accumulation in cancer 
cells and thus conferring multidrug resistance (MDR) (Glavinas et al., 2004). They have next 
been shown to be expressed at various anatomical/histological sites, known to play a major 
role for xenobiotic disposition, such as intestine, blood-tissue barriers like the blood-brain 
barrier, liver and kidney (Konig et al., 2013). In this way, ABC drug transporters play a major 
role in the different steps of pharmacokinetics, which are absorption, distribution and hepatic 
and renal elimination (Giacomini et al., 2010), and beyond, in drug efficacy and toxicity 
(DeGorter et al., 2012). Modulation of their activity and/or their expression may therefore 
have notable consequences for drug disposition and activity, and has consequently to be 
addressed during the pharmaceutical development of new molecular entities according to a 
regulatory point of view (Prueksaritanont et al., 2013).  
ABC transporters, including P-glycoprotein, encoded by the MDR1 (ABCB1) gene, 
breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 
(MRP) 1 (ABCC1), are also expressed in the lung epithelium (Courcot et al., 2012; Endter et 
al., 2007; Sakamoto et al., 2015). They therefore likely contribute to the lung barrier and, in 
this way, may be involved in pulmonary absorption of xenobiotics (Bosquillon, 2010; 
Ehrhardt et al., 2017), including that of noxious compounds such as air pollutants and 
cigarette smoke components (van der Deen et al., 2005). They may also participate in lung 
protection towards volatile toxicants (Leslie et al., 2005). They may additionally be involved 
in the release of inflammatory mediators such as uric acid, leukotrienes and prostaglandins, 
which are substrates for some ABC transporters (Nakayama et al., 2011; Rius et al., 2008). 
This may contribute to lung toxicity caused by air pollutants (Gold et al., 2016; Schneider et 
al., 2005). The potential relationship between ABC transporters and atmospheric pollutants is 
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moreover supported by the fact that diesel exhaust particle (DEP) extract (DEPe) as well as 
cigarette smoke condensate (CSC) have been shown to induce expression of BCRP, MRP3 
(ABCC3) and MRP4 (ABCC4) in cultured human hepatic cells (Le Vee et al., 2015; Sayyed et 
al., 2016). However, whether pulmonary expression of ABC drug transporters may also be 
regulated by inhaled pollutants remains mainly unknown. The lung being the primary and 
main site of exposure to these pollutants, their effects on pulmonary expression of ABC drug 
transporters are probably important to assess. In order to gain insights about this point in the 
present study, and owing to the relevance of human exposure to diesel exhaust (Steiner et al., 
2016), we have analyzed the effects of DEPe on ABC drug transporter expression in human 
bronchial epithelial BEAS-2B cells, used here as in vitro lung epithelium model responsive to 
DEPe (Cao et al., 2010; Le Vee et al., 2016). Our data demonstrate that treatment by DEPe 
induces expression of the ABC transporter MRP3 in BEAS-2B cells, in an aryl hydrocarbon 
receptor (AhR)- and nuclear-factor-E2-related factor 2 (Nrf2)-dependent manner. Such data 
support the idea that air pollutants, including DEPs, may target ABC transporters in the lung.  
 
2. Materials and Methods 
2.1 Chemicals  
DEPe used in the study was the standard reference material (SRM) 1975, provided by 
the National Institute of Standards and Technology (Gaithersburg, MD, USA). It is a 
dichloromethane extract of filter-collected combustion particulate matter, referenced as SRM 
2975, from operating forklifts with diesel engines (Hughes et al., 1997). It notably contains 
polycyclic aromatic hydrocarbons (PAHs) and nitro-PAHs (Manzano et al., 2013). For cell 
exposure, dichloromethane was evaporated under nitrogen and the final residue was dissolved 
in dimethyl sulfoxide (DMSO). Probenecid, sulforaphane, benzo(a)pyrene (B(a)P), 
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StemRegenin-1 and pifithrin-α were purchased from Sigma-Aldrich (Saint-Quentin Fallavier, 
France), whereas 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was obtained from Cambridge 
Isotope Laboratories (Cambridge, MA, USA). Carboxy-2,7-dichlorofluorescein (CF) diacetate 
was from Life Technologies (Paisley, United Kingdom).  
2.2 Cell culture 
The human bronchial epithelial cell line BEAS-2B as well as normal human bronchial 
epithelial (NHBE) cells (isolated from epithelial lining of airways above bifurcation of the 
lungs from normal donors and provided by Lonza, Basel, Switzerland) were cultured in 
BEBMTM bronchial epithelial cell growth basal medium, supplemented with BEGMTM 
bronchial epithelial cell growth medium BulletKitTM (Lonza). BEAS-2B cells were usually 
seeded at 18 x 103 cells/cm2 and treated by DEPe at confluency stage. Chemicals were 
initially dissolved in DMSO and stored frozen as stock solutions until use. Final concentration 
of solvent in culture media did not exceed 0.2% (vol/vol); control cultures received the same 
dose of DMSO as for their treated counterparts. When chemical inhibitors were used, they 
were added 15 min before DEPe treatment. 
2.3 Cytotoxicity assay 
Cellular apoptosis or necrosis were investigated through cell staining with 10 μg/mL 
Hoechst 33342 and 1 μg/mL propidium iodide for 15 min at 37 °C, as previously described 
(Sayyed et al., 2016). Apoptotic cells, i.e., cells with condensed blue chromatin or fragmented 
blue nuclei, and necrotic cells, i.e., cells with red nuclei, were next counted in comparison 
with total cell population using fluorescence microscopy. The percentage of viable cells, 
defined as non-apoptotic and non-necrotic cells, was deduced by subtracting the percentages 
of apoptotic and necrotic cells from 100% (total cell number).  
2.4 RNA isolation and analysis  
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Total RNAs were extracted from cells using the TRI reagent (Sigma-Aldrich), and 
were then reverse-transcribed to cDNA using the reverse-transcription (RT) kit from Applied 
Biosystems (Foster City, CA, USA). Quantitative polymerase chain reaction (qPCR) assays 
were next performed using the fluorescent dye SYBR Green methodology and a CFX384 
real-time PCR detection system (Bio-Rad, Marnes-la-Coquette, France), as previously 
described (Mayati et al., 2018). Gene primers are described in Table S1. The specificity of 
each gene amplification was verified at the end of qPCR reactions through analysis of 
dissociation curves of the PCR products. Amplification curves were analyzed with CFX 
Manager software (Bio-Rad), using the comparative cycle threshold method. Relative 
quantification of the steady-state target mRNA levels was calculated after normalization of 
the total amount of cDNA tested to the 18S rRNA endogenous reference, using the 2(−ΔΔCt) 
method. Data were finally commonly expressed as fold change comparatively to control 
untreated cells or in arbitrary units relatively to 18S rRNA content (Moreau et al., 2011).  
2.4 RNA interference assays 
Control non-targeting siRNAs (siNT) or siRNAs targeting AhR (siAhR) or Nrf2 
(siNrf2), provided by Sigma-Aldrich and prepared in Opti-MEM medium (ThermoFischer 
Scientific, Waltham, MA, USA) at a final 0.4 µM concentration, were incubated overnight at 
37°C in the presence of 12 μL/mL of Lipofectamine RNAiMax TM (ThermoFisher Scientific) 
with BEAS-2B cells plated in 24 wells plates. Transfected BEAS-2B cells were next 
maintained in usual medium for 48 h before treatment by DEPe.  
2.5 Western-blotting 
Total protein extracts were prepared from BEAS-2B cells as previously reported (Le 
Vee et al., 2016). Protein were then separated on polyacrylamide gel and electrophoretically 
transferred onto Protan® nitrocellulose membranes (Whatman GmbH, Dassel, Germany). 
After blocking with Tris-buffered saline containing 4 % (vol/vol) bovine serum albumin and 
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0.1% (vol/vol) Tween 20 for 30 min at room temperature, membranes were incubated 
overnight at 4°C with primary antibodies against MRP3 (clone M3II-9) (Enzo Life Sciences, 
Villeurbanne, France) or p38 (clone C20) (Santa Cruz Biotechnology, Dallas, TX, USA). 
After washing, membranes were next re-incubated with appropriate horseradish peroxidase-
conjugated secondary antibodies (Dako, Glostrup, Denmark). Immunolabeled proteins were 
finally visualized by chemiluminescence. Gel loading and transfer were verified by staining 
membranes with Ponceau red. Densitometry with ImageJ 1.40g software (National Institutes 
of Health, Bethesda, MD, USA) was used to quantify intensities of stained bands and for 
normalization to p38 content.  
2.6   MRP activity assay 
MRP activity was analyzed through measuring intracellular retention of the MRP 
substrate CF, as previously described (Jouan et al., 2016). Briefly, BEAS-2B cells were 
incubated at 37°C with 3 μM CF diacetate for 30 min. After washing in phosphate-buffered 
saline, cells were re-incubated in CF diacetate-free medium at 37°C for 60 min in the 
presence or absence of DEPe or of 2 mM probenecid, a reference inhibitor of MRPs (Rosati et 
al., 2004). Intracellular retention of CF was next determined by spectrofluorimetry (excitation 
and emission wavelengths were 485 and 535 nm, respectively) using a SpectraMax Gemini 
SX spectrofluorometer (Molecular Devices, Sunnyvale, CA, USA). Protein content was in 
parallel determined by the Bradford method. Data were expressed as % of CF initial loading, 
as CF fluorescence arbitrary unit/mg protein or as % of MRP activity according to the 
following equation: 
% MRP activity =
(CF RetentionProbenecid - CF Retention
DEPe) x 100
CF RetentionProbenecid - CF Retention
Control
 
             (1) 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
8 
 
with CF RetentionProbenecid = CF retention in the presence of probenecid, CF RetentionDEPe = 
CF retention in the presence of DEPe and CF RetentionControl = CF retention in control cells 
not exposed to probenecid or DEPe. 
2.7 Statistical analysis 
Quantitative data were usually expressed as means ± SEM. Data were statistically 
analyzed using Student's t test or analysis of variance (ANOVA) followed by Dunnett’s or 
Newman-Keuls post-hoc test. The criterion of significance was p < 0.05. Half maximal 
inhibitory concentration (IC50) value of DEPe towards MRP activity was determined using 
GraphPad Prism software (GraphPad Software, La Jolla, CA), through nonlinear regression 
based on the four parameter logistic function. 
3. Results 
3.1 Induction of MRP3 expression by DEPe 
BEAS-2B cells were first exposed for 48 h to 10 µg/mL DEPe, a DEPe concentration 
in the range of those previously used for treating cultured cells (Bach et al., 2015; Le Vee et 
al., 2015; Mundandhara et al., 2006). Such a treatment failed to trigger apoptosis or necrosis 
(Fig. 1). Among ABC transporter mRNA expressions, that of MDR1 was not detected in both 
untreated control BEAS-2B cells and DEPe-exposed counterparts (Fig. 2A). Those of BCRP, 
MRP2, MRP5 and MRP6 were low in untreated BEAS-2B cells (mRNA level means < 2 
arbitrary units) and were either unchanged (BCRP and MRP5) or reduced (MRP2 and MRP6) 
by DEPe (Fig. 2A). MRP1, MRP3 and MRP4 were the most expressed ABC drug transporters 
in BEAS-2B cells (mRNA level means > 8 arbitrary units). DEPe treatment decreased MRP1 
and MRP4 levels, by 1.5 ± 0.2-fold and 1.6 ± 0.1-fold factors, respectively; by contrast, it 
induced that of MRP3 by a 3.3 ± 0.9-fold factor. As (i) MRP3 was the ABC drug transporter 
exhibiting the higher mRNA expression in BEAS-2B cells (Fig. 2A), (ii) it was the only to 
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display mRNA up-regulation in response to DEPe and (iii) it may be implicated in lung 
diseases, notably in lung cancers (Hanada et al., 2008; Young et al., 1999), we decided to 
focus the next studies on DEPe-mediated MRP3 up-regulation. Time-course analysis (Fig. 
2B) indicated that a short DEPe-treatment (8 h) failed to induce MRP3 mRNA expression, in 
contrast to longer treatments (24 h and 48 h). DEPe-mediated MRP3 mRNA up-regulation 
was next shown to be concentration-dependent, i.e., it required a 10 µg/mL DEPe 
concentration, whereas lower concentrations (from 0.1 to 5 µg/mL) were inactive (Fig. 2C). 
The effects of DEPe concentrations higher than 10 µg/mL on MRP3 mRNA levels were not 
studied as such concentrations were found to be cytotoxic (data not shown). DEPe was 
demonstrated to enhance MRP3 protein expression in BEAS-2B cells by a 2.6-fold factor 
(Fig. 2D). Finally, we investigated the effects of DEPe on MRP3 expression in NHBE cells 
from three donors. Constitutive MRP3 mRNA levels were clearly detectable (mRNA level>2 
arbitrary units) in NHBE cells from each donor (Fig. S1). DEPe (10 µg/ mL) was found to 
induce MRP3 mRNA expression in these NHBE cells by a 5.7 ± 0.7-fold factor (Fig. 2E). 
3.2 Inhibition of MRP activity by DEPe 
DEPe has previously been shown to inhibit MRP2-like activity in human hepatic 
HepaRG cells (Le Vee et al., 2015). As MRPs, notably MRP1, MRP2 and MRP3, share 
numerous inhibitors (Payen et al., 2000; Zhou et al., 2008), DEPe may be postulated to also 
block MRP activity in bronchial BEAS-2B cells. To test this hypothesis, we initially loaded 
BEAS-2B cells with the generic MRP substrate CF and next analyzed the efflux of the dye in 
the absence or presence of 10 µg/mL DEPe or of 2 mM probenecid. As shown in Fig. 3A, 
BEAS-2B cells exhibited probenecid-inhibitable efflux of CF, indicating that they 
constitutively displayed MRP activity. Addition of 10 µg/mL DEPe during the efflux period 
significantly enhanced CF retention in BEAS-2B cells, indicating that DEPe inhibited MRP 
activity. This inhibitory effect towards MRP activity was next shown to be concentration-
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dependent (DEPe IC50 value = 10.0 µg/mL) (Fig. 3B). We next investigated whether BEAS-
2B cells exposed to DEPe treatment conditions known to trigger MRP3 induction, i.e., a 48 h 
exposure to 10 µg/mL DEPe, exhibit impaired MRP activity. For such a purpose, DEPe was 
withdrawn during the efflux assay, in order to study only the effects of the prior 48 h exposure 
to DEPe. As indicated in Fig. 3C, the levels of CF retention after the efflux phase were not 
different in both untreated and DEPe-exposed cells.  
3.3 Implication of AhR in DEPe-mediated MRP3 induction 
The regulatory effects of DEPe towards hepatic transporter expression implicate AhR 
(Le Vee et al., 2015), a xenobiotic-sensing receptor known to be activated by some 
components of DEPe, notably PAHs (Mason, 1994; Palkova et al., 2015). We therefore 
studied the implication of AhR in DEPe-mediated induction of MRP3 in bronchial BEAS-2B 
cells. The AhR pathway was first shown to be activated by DEPe in BEAS-2B cells, as 
demonstrated by (i) the up-regulation of the reference AhR target gene cytochrome P-450 
(CYP) 1B1 (Nebert et al., 2004) in DEPe-exposed BEAS-2B cells and (ii) the suppression of 
this up-regulation by co-treatment with StemRegenin-1, a potent antagonist of AhR (Boitano 
et al., 2010) (Fig. 4A). CYP1B1 mRNA induction was maximal at an 8 h exposure to DEPe 
(Fig. S2) and was thus faster than that of MRP3 (Fig. 2B). The AhR blocker StemRegenin-1 
hindered MRP3 mRNA up-regulation due to DEPe (Fig. 4A). Transfection of BEAS-2B cells 
with siRNAs directed against AhR, resulting in a strong repression of AhR mRNA by a 3.8 ± 
0.3-fold factor (Fig. S3), inhibited DEPe-mediated up-regulation of CYP1B1 and MRP3 (Fig. 
4B). To determine if AhR activation was sufficient to trigger MRP3 induction, we next 
studied the effects of TCDD, a potent and reference activator of AhR (Okey et al., 1994). As 
shown in Fig. 4C, TCDD markedly induced mRNA expression of CYP1B1, but failed to 
enhance that of MRP3. By contrast, exposure of BEAS-2B cells to the prototypical PAH 
B(a)P increased both CYP1B1 and MRP3 mRNA levels (Fig. 4C). 
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3.4 Implication of Nrf2 in DEPe-mediated MRP3 induction 
As Nrf2, a transcription factor activated by oxidative stress (Nguyen et al., 2004), is 
involved in both MRP3 regulation (Mahaffey et al., 2009) and DEP effects (Jaguin et al., 
2015; Li et al., 2004), we analyzed its role in MRP3 up-regulation by DEPe. We first 
demonstrated that the Nrf2-related MRP3 regulation pathway was active in BEAS-2B cells, 
through showing that sulforaphane, a potent Nrf2 activator (Thimmulappa et al., 2002), 
induced MRP3 mRNA and protein expression in BEAS-2B cells (Fig. 5A and 5B). DEPe 
exposure was next shown to induce mRNA expression of the reference Nrf2 target genes 
NQO1 (Tanigawa et al., 2007) and HO-1 (Alam and Cook, 2003) (Fig. 5C), indicating that 
the Nrf2 signaling pathway was activated by DEPe in BEAS-2B cells, as already 
demonstrated in other lung cell lines (Baulig et al., 2003). Transfection of BEAS-2B cells by 
siRNAs targeting Nrf2, which reduced Nrf2 mRNA expression by a 3.7 ± 0.4-fold factor (Fig. 
S3), markedly decreased MRP3 mRNA induction by DEPe and sulforaphane (Fig. 5D). By 
contrast, Nrf2 silencing did not impair up-regulation of CYP1B1 mRNA levels by DEPe. 
Sulforaphane failed to increase CYP1B1 expression (Fig. 5D) and its inducing effect towards 
MRP3 and NQO1 mRNA levels was not impaired by AhR silencing (Fig. S4). Besides, AhR 
or Nrf2 down-regulations by siRNA transfection repressed NQO1 mRNA induction by DEPe 
(Fig. S5). Finally, pifithrin-α, a potent inhibitor of CYP1A1/1B1 activity preventing the 
formation of PAH metabolites (Sparfel et al., 2006), failed to inhibit MRP3 up-regulation due 
to DEPe (Fig. S6). 
 
4. Discussion 
 The present study demonstrates that DEPe is able to induce MRP3 expression in 
bronchial epithelial cells. Indeed DEPe increased MRP3 mRNA levels in both BEAS-2B cells 
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and NHBE cells. It concomitantly induced MRP3 protein expression in BEAS-2B cells. This 
up-regulation of MRP3 by DEPe was concentration-dependent, i.e., it requires the use of 10 
µg/mL DEPe. Such a concentration failed to trigger cytotoxicity in BEAS-2B cells. MRP3 
up-regulation was consequently not the consequence of an unspecific toxicity caused by 
DEPe. The specificity of the MRP3 up-regulation by DEPe is additionally supported by the 
fact that DEPe did not induce expression of other ABC transporters; indeed, MRP1 and 
MRP4 mRNA expressions were rather reduced by DEPe, whereas those of MRP5 and BCRP 
were unchanged. With respect to MDR1, we failed to detect its expression at mRNA levels, in 
both untreated and DEPe-treated BEAS-2B cells. Drug transporter quantification by liquid 
chromatography-tandem mass spectrometry also failed to detect P-glycoprotein in BEAS-2B 
cells (Sakamoto et al., 2015). Taken together, these data suggest that BEAS-2B cells do not 
constitutively express P-glycoprotein/MDR1 and are thus probably not a valuable model for 
studying P-glycoprotein/MDR1 regulation in bronchial cells. Additionally, BEAS-2B cells 
unfortunately failed to polarize and form tight junctions, and exhibited only very low, if any, 
transepithelial electrical resistance (TEER) values (Stewart et al., 2012). This precludes their 
use for in vitro characterization of the effects of air pollutants like DEP on vectorial transport 
across the lung barrier.  
 The mechanisms responsible for MRP3 induction by DEPe in BEAS-2B cells likely 
implicate AhR, a xenobiotic-sensing transcription factor already involved in DEPe-mediated 
regulation of hepatic drug transporters (Le Vee et al., 2015). Indeed, the AhR antagonist 
StemRegenin-1, as well as AhR silencing through siRNA transfection, repressed MRP3 
induction in DEPe-exposed BEAS-2B cells. It is however noteworthy that the potent AhR 
ligand TCDD failed to increase MRP3 mRNA levels in BEAS-2B cells, thus indicating that 
AhR activation is not sufficient to induce MRP3 expression. Factors additional to AhR are 
consequently required for MRP3 up-regulation and, among these putative factors, Nrf2 has to 
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be considered with priority. This transcription factor is primarily responsive to oxidative or 
electrophilic stress, which prevents its degradation by the proteasome and subsequently 
triggers its translocation from the cytoplasm into the nucleus, where it binds to antioxidant 
response element (ARE) found in the upstream promoter of target genes, and initiates their 
transcription (Nguyen et al., 2004). Nrf2 is well known to be activated by DEPs (Li et al., 
2004), as illustrated by the up-regulation of NQO1 and HO-1, two reference Nrf2-responsive 
genes, in DEPe-exposed BEAS-2B cells. Its implication in DEPe-mediated induction of 
MRP3 is supported by the following points: (i) treatment by the reference Nrf2 activator 
sulforaphane triggered MRP3 induction in BEAS-2B cells, (ii) suppression of Nrf2 expression 
by siRNA transfection repressed MRP3 up-regulation due to DEPe, (iii) analysis of the MRP3 
promoter sequence has revealed the presence of multiple AREs (Mahaffey et al., 2009), 
mediating direct regulation of MRP3 by Nrf2 (Mahaffey et al., 2012) and (iv) Nrf2, in 
association with AhR, has already been demonstrated to be involved in various phenotypic 
effects of DEPe, notably in human macrophages (Jaguin et al., 2015).  
 The exact way by which AhR and Nrf2 cooperate to induce MRP3 expression in 
response to DEPe remains to be determined. Basic implication of the AhR pathway in that of 
Nrf2 or, inversely, basic involvement of the Nrf2 signaling cascade in that of AhR is very 
unlikely. Indeed, silencing of Nrf2 is unable to hinder AhR-related induction of the AhR 
reference target CYP1B1 by DEPe, whereas that of AhR failed to impair up-regulation of the 
Nrf2 target NQO1 by sulforaphane. Additionally, the two ways are probably not involved at 
the same level in MRP3 up-regulation. Indeed, if basic activation of the Nrf2 signaling 
pathway by the reference activator sulforaphane is sufficient to induce MRP3 expression, 
likely via the AREs found in the upstream promoter region of the MRP3 gene (Mahaffey et 
al., 2009), it is not the case for the basic stimulation of the AhR signaling cascade by the 
reference AhR agonist TCDD. In this context, it is noteworthy that the AhR way is well-
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known to play a major role in the metabolism of some of these ligands, notably PAHs, 
through inducing the expression of PAHs-metabolizing enzymes like CYP1A1 and CYP1B1 
(Nebert et al., 2004). Some of these PAH metabolites are known to be electrophilic and to 
induce oxidative stress (Nebert et al., 2000). They may thus contribute in a major way to the 
activation of the Nrf2 transcription battery by PAHs (Souza et al., 2016). It is therefore 
tempting to speculate that the MRP3 induction by DEPe, as well as that of NQO1, which also 
depends on AhR and Nrf2 (Fig. S5), may require, first, the AhR-dependent formation of 
electrophilic/pro-oxidative metabolites of some DEPe chemical components, notably PAHs, 
and, secondly, the activation of the Nrf2 pathway by these metabolites or by the oxidative 
stress associated with the generation of these metabolites. This may finally result in increased 
transcription of the MRP3 gene via AREs. This hypothesis is supported by the fact that the 
PAH B(a)P, which is a component of diesel exhaust and which generates electrophilic 
metabolites, in contrast to TCDD (van Grevenynghe et al., 2004), induced MRP3 expression 
in BEAS-2B cells. Moreover, the time-course of MRP3 mRNA induction by DEPe indicates a 
rather delayed response, i.e., a shorter exposure (8 h) was ineffective, which may also argue in 
favor of the requirement of metabolite formation. By contrast, the pure AhR target CYP1B1 
was induced after an 8 h exposure to DEPe. CYP1B1, as well as CYP1A1, well known to 
generate electrophilic PAH metabolites (Nebert et al., 2004), are however unlikely to be 
involved in MRP3 up-regulation in DEPe-exposed BEAS-2B cells. Indeed, blockage of their 
activity using the CYP1A1/1B1 inhibitor pifithrin-α failed to inhibit MRP3 induction by 
DEPe.  
 Besides increasing MRP3 expression, DEPe directly inhibited MRP activity in BEAS-
2B cells, in a concentration-dependent manner (Fig. 3A and 3B). This agrees with the 
inhibitory effects of DEPe towards MRP2-like activity in human hepatic cells (Le Vee et al., 
2015). Such data favor the idea that some chemical components of DEPe may act as potent 
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inhibitors of MRP activity. However, these DEPe chemicals remain to be precisely identified. 
They may also be present in other pulmonary pollutants, such as the cigarette smoke, which 
hinders MRP1 activity in lung epithelial cells (van der Deen et al., 2007). The direct inhibition 
of MRP activity by DEPs and the regulation of MRP expression, notably of MRP3, by DEPe, 
may be difficult to interpret in terms of the final effects of DEPe towards MRPs. It is however 
noteworthy that the MRP activity inhibition by DEPe was rather reversible, i.e., pre-treatment 
by DEPe for 48 h following by its withdrawal during the MRP activity test, failed to inhibit 
MRP activity (Fig. 3C), whereas such a 48 h treatment by DEPs induced MRP3 expression 
(Fig. 2B and Fig. 2D). This suggests that the regulation of MRP expression, notably MRP3 
induction, may correspond to a more sustainable consequence to DEP exposure than the acute 
inhibition of MRP activity. In this context, it is noteworthy that MRP3 induction after a 48 h 
exposure to DEPe did not result in decreased CF retention, suggesting a lack of stimulatory 
effect towards MRP activity. Such data may be due to the fact that the probe used for the 
MRP activity assay, i.e., CF, is shared by various MRPs, as most of MRP3 substrates (Payen 
et al., 2000; Zhou et al., 2008); therefore, the CF-based efflux assay likely reflects global 
MRP activity, not strictly that of MRP3. Nevertheless, as MRP3 has been hypothesized to be 
a cellular eliminator of toxins from both endogenous and exogenous sources in lung cells 
(Torky et al., 2005), its increased expression in response to DEPe may serve as an adaptive 
and protective response to the potential toxicity of DEP components.  MRP3 induction may 
notably facilitate anti-oxidant activities within DEP-exposed bronchial cells, as recently 
proposed for MRP3 up-regulation in airway epithelial cells from smokers (Aguiar et al., 
2019).    
Whether the MRP3 regulation occurring in DEPe-treated cultured bronchial cells may 
be relevant in humans environmentally exposed to DEPs is probably a key-point to determine. 
This likely requires to consider the concordance between in vitro-in vivo dosimetry, which 
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represents a common challenge in air pollutant toxicology (Donaldson et al., 2008; Klein et 
al., 2017; Oberdorster and Finkelstein, 2006). The mean DEP exposure in the United States of 
America is estimated to be 2 µg/m3, but concentrations in vehicles and by major streets and 
highways can approach 25 µg/m3, with “hot spots” of ambient exposure reaching around 100-
200 µg/m3 (Ghio et al., 2012); some occupational activities, notably in mines, result in much 
greater levels of exposure (up to 653 µg/m3) (Pronk et al., 2009). Based on in vivo 
calculations for high-risk individuals exposed to particulate matter levels of 79 μg/m3, 
deposition rates of fine particulate matter (PM 2.5), which represents an important fraction of 
DEP (Wichmann, 2007), have been estimated over 24 h to be 2.3 μg/cm2 in the 
tracheobronchial and 0.05 μg/cm2 in the alveolar regions (Li et al., 2003). Importantly, the 10 
µg/mL DEPe concentration inducing MRP3 expression in BEAS-2B cells corresponds to 
approximately 2 μg/cm2 equivalent DEP dose according to previous conversions of in vitro 
DEPe/DEP dose to DEP dose/unit surface area (Li et al., 2003). MRP3 expression may 
therefore be induced in tracheobronchial, but not in alveolar areas, of humans highly exposed 
to DEP. The fact that MRP3 mRNA expression has been recently shown to be induced in 
airway epithelial cells from smokers when compared to counterparts from non-smokers 
(Aguiar et al., 2019) additionally supports the conclusion that MRP3 may be a relevant target 
for air pollutants like DEP and cigarette smoke in the human lung. 
 In summary, exposure of bronchial epithelial BEAS-2B cells to DEPe resulted in 
AhR- and Nrf2-related induction of the ABC drug transporter MRP3. DEPe additionally 
directly inhibited MRP activity in BEAS-2B cells. Such data suggest that membrane 
transporters, including ABC transporters, but also solute carrier (SLC) transporters like the 
heterodimeric amino acid transporter LAT1 (SLC7A5)/CD98hc (SLC3A2) already 
demonstrated to be regulated by DEPe in BEAS-2B cells (Le Vee et al., 2016), are targets for 
DEPs in bronchial epithelial cells. Further studies are likely required to precise the potential 
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relevance of such regulations in humans exposed to air pollution, notably in terms of lung 
barrier and lung toxicity. 
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Legends to figures 
Figure 1. Effects of DEPe exposure on BEAS-2B cell viability. BEAS-2B cells were either 
untreated (CTR) or exposed to 10 µg/mL DEP for 48 h. Apoptotic and necrotic cells were 
next numerated as described in Materials and Methods. Data are expressed as percentages of 
total number of cells and are the means ± SEM of three independent assays.  
Figure 2. Induction of MRP3 expression in response to DEPe. (A) BEAS-2B cells were either 
untreated (CTR) or exposed to 10 µg/mL DEPe for 48 h. ABC drug transporter mRNA 
expression was then analyzed by RT-qPCR. Data are expressed as arbitrary units and are the 
means ± SEM of five independent assays. *, p < 0.05 when compared to control untreated 
cells. (B, C) BEAS-2B cells were either untreated (CTR) or exposed to (B) 10 µg/mL DEPe 
for various lengths of time (from 8 h to 48 h) or (C) various DEPe concentrations (from 0.01 
to 10 µg/mL) for 48 h. MRP3 mRNA expression was next determined by RT-qPCR. Data are 
expressed as fold change comparatively to MRP3 mRNA levels found in untreated control 
cells and are the means ± SEM of (B) five or (C) three independent assays. *, p <0.05 when 
compared to control untreated cells. (D) BEAS-2B cells were either untreated (CTR) or 
exposed to 10 µg/mL DEPe for 48 h. MRP3 protein expression was next determined by 
Western-blotting. A representative blot is shown in (D, Left). The results of densitometric 
analysis of blots and normalization to p38 content from three independent assays, expressed 
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as fold change comparatively to MRP3 protein expression in control cells, are indicated in (D, 
Right). *, p < 0.05 when compared to control cells. (E) NHBE cells were either untreated 
(CTR) or exposed to 10 µg/mL DEPe for 24 h. MRP3 mRNA expression was then analyzed 
by RT-qPCR. Data are expressed as fold change comparatively to MRP3 mRNA levels found 
in untreated control cells and are the means ± SEM of values from three independent NHBE 
cell populations. *, p < 0.05 when compared to control untreated cells.  
Fig. 3. Effects of DEPe towards MRP activity. (A) BEAS-2B cells, initially loaded with the 
MRP substrate CF used under its diacetate ester form, were re-incubated in CF-free medium 
in the absence (CTR) or presence of 2 mM probenecid or 10 µg/mL DEPe for 60 min. 
Intracellular retention of CF was then determined by spectrofluorimetry. Data are expressed 
as % of initial CF loading and are the means ± SEM of three independent assays. *, p < 0.05 
when compared to control cells. (B) CF-loaded BEAS-2B cells were re-incubated in CF-free 
medium in the absence or presence of 2 mM probenecid or various concentrations of DEPe. 
MRP activity was then determined as described in Materials and Methods. Data are expressed 
as % of MRP activity found in control cells and are the means ± SEM of three independent 
assays. DEPe IC50 value is indicated at the top of the graph. (C) BEAS-2B cells were either 
untreated (CTR) or exposed to 10 µg/mL DEPe for 48 h. After washing, cells were loaded 
with CF used under its diacetate form for 30 min and then re-incubated in CF-free medium for 
60 min. Intracellular levels of CF were finally determined by spectrofluorimetry. Cellular 
concentrations of CF are expressed in fluorescence arbitrary units (FAU)/mg protein and are 
the means ± SEM of four independent assays. *, p < 0.05; NS, not statistically significant. 
Fig. 4. Implication of AhR in DEPe-mediated MRP3 induction. (A) BEAS-2B cells were 
either untreated (CTR) or exposed to 10 µg/mL DEPe, 5 µM StemRegenin-1 (SR) or 
DEPe/SR for 48 h. (B) BEAS-2B cells transfected with non-targeting siRNAs (siNT) or with 
siRNAs directed against AhR (siAhR) were either untreated (CTR) or exposed to 10 µg/mL 
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DEPe for 48 h. (C) BEAS-2B cells were either untreated (CTR) or exposed to 10 nM TCDD 
or 10 µM B(a)P for 48 h. (A-C) CYP1B1 and MRP3 mRNA expression was next determined 
by RT-qPCR. Data are expressed as fold change comparatively to gene expression in control 
cells and are the means ± SEM of four independent assays. *, p < 0.05; NS, not statistically 
significant. 
Fig. 5. Implication of Nrf2 in DEPe-mediated MRP3 regulation. (A, B) BEAS-2B cells were 
either untreated (CTR) or exposed to 10 µM sulforaphane (SULFO) for 48 h. (A) MRP3 
mRNA expression was determined by RT-qPCR; data are expressed as fold change 
comparatively to untreated control cells and are the means ± SEM of four independent assays. 
(B) MRP3 protein expression was determined by Western blotting. A representative blot is 
shown in (B, Up). The results of densitometric analysis of blots and normalization to p38 
content from three independent assays, expressed as fold change comparatively to MRP3 
protein expression in control cells, are indicated in (B, Down). (C) BEAS-2B cells were either 
untreated (CTR) or exposed to 10 µg/mL DEPe for 48 h. NQO1 and HO-1 mRNA expression 
was then determined by RT-qPCR. Data are expressed as fold change comparatively to 
untreated control cells and are the means ± SEM of four independent assays. (A-C) *, p < 
0.05 when compared to control cells. (D) BEAS-2B cells transfected with non-targeting 
siRNAs (siNT) or with siRNAs directed against Nrf2 (siNrf2) were either untreated (CTR) or 
exposed to 10 µg/mL DEPe for 48 h. MRP3 and CYP1B1 mRNA expression was then 
determined by RT-qPCR. Data are expressed as fold change comparatively to untreated 
control cells and are the means ± SEM of four independent assays. *, p < 0.05. NS, not 
statistically significant. 
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Highlights 
 
- DEPe induced mRNA and protein expression of MRP3 in human bronchial BEAS-2B cells 
- The transcription factors AhR and Nrf2 are implicated in DEPe-mediated MRP3 induction 
- DEPe concomitantly blocked MRP activity in cultured BEAS-2B cells 
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